CERo Therapeutics Holdings, Inc. CERO
0.01
0.00
0.00%
as of 25 Sep
- Market cap
- $140.0K
- P/E
- 0.0×
Follow CERO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
0.30 | 0.30 | 0.14 | 0.05 |
Net Debt/EBITDA |
0.49 | 0.40 | 0.16 | 0.06 | |
Debt/Assets |
0.00% | 0.00% | 6.20% | 39.29% | |
Debt/Equity |
0.00 | 0.00 | (0.01) | (0.02) | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.28 | 0.08 | 0.47 | 0.08 | |
Capex/Depreciation |
1.83 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(2.14) | (0.90) | (0.10) | (0.06) | |
Cash per Share |
1.60 | 0.39 | 0.03 | 0.02 | |
Shareholders Equity per Share |
(3.59) | (1.29) | (0.32) | (0.72) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(3.59) | (1.29) | (0.32) | (0.72) | |
Free Cash Flow |
(2.71) | (3.81) | (2.76) | (2.33) | |
Working Capital |
(5.90) | (6.35) | (9.75) | (30.86) | |
Capital Expenditures |
0.50 | 0.00 | — | — | |
Net Current Asset Value |
(5.90) | (6.35) | (9.89) | (30.86) | |
| Other line items | |||||
Quick Ratio |
0.24 | 0.18 | 0.08 | 0.03 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.53) | (0.90) | (0.10) | (0.06) | |
Capex per Share |
0.40 | 0.00 | 0.00 | 0.00 | |
Average Payables |
6.87 | 6.04 | 7.03 | 7.21 | |
Average Assets |
5.20 | 4.92 | 5.10 | 4.05 | |
Average Common Equity |
(10.26) | (8.89) | (9.62) | (21.00) | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates